Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vildagliptin (dipeptidyl peptidase-4) with metformin reduced the incidence of hypoglycaemia, compared to a sulphonylurea (SU) with metformin combination, in muslim people with type 2 diabetes fasting during Ramadan, according to Vector study by Novartis.
Subscribe to our email newsletter
The Vector, a real-life, prospective comparative study proved that the patients who received Vildagliptin and metformin did not experienced hypoglycaemic or severe hypoglycaemic events.
However, the combination treatment of SU with metformin showed 34 hypoglycaemic events, including one severe event, reported in 15 people receiving an SU and metformin.
The Vector study also demonstrated that tolerability and adherence to treatment was markedly better in the Vildagliptin and metformin treated cohort than those treated with SU and metformin.
The patients treated with Vildagliptin and metformin also experienced a significantly lower HbA1c measurement, post-Ramadan (7.7% to 7.2%) versus those treated with an SU and metformin (7.2% to 7.3%).
The University of Birmingham Medicine professor and consultant physician Anthony Barnett said the real-life data from the Vector study show Vildagliptin with metformin is an effective treatment option with low risk of the unpleasant and sometimes devastating consequences of hypoglycaemia.